To provide a tumor-specific mutant of B-Raf gene, a method for diagnosing tumor, and a method for developing therapeutic drugs for treating tumor.
Mutations described are identified in human tumors, wherein the mutations are seen in a natural mutant human B-Raf polypeptide comprising one or more amino acid mutations in tumor-associated somatic cells. These mutations are associated with cancerous phenotypes and can be used for a method for detecting carcinogenic mutations by inspecting nucleic acid substances derived from at least a part of B-Raf genes in human subjects, a method for detecting mutant B-Raf polypeptides using antibodies, and further the development of anti-cancer therapeutics on the basis of a method for identifying one or more compounds having anti-proliferation activity.
FUTREAL ANDY
WOOSTER RICHARD
MARAIS RICHARD MALCOLM
MARSHALL CHRIS
JPN6010056394, Ｎａｔｕｒｅ, 2002, ｖｏｌ． ４１７, ９４９−９５４
JPN6008032394, Ｍｏｌ． Ｃｅｌｌ． Ｂｉｏｌ．, 1999, ｖｏｌ． １９, ６０５７−６０６４
JPN6008032393, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 2000, ｖｏｌ． ２７５, ３８０３−３８０９
JPN6008032391, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 2000, ｖｏｌ． ２７５, ２７３５４−２７３５９
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Next Patent: EphA2 MONOCLONAL ANTIBODY AND USE OF THE SAME